“With respect to our products, for [indiscernible], we continue to expect a negative impact to U.S. sales, given the shift towards new adults pneumococcal vaccine.”

In context

“g underlying momentum of our business will continue into the second half of the year. As you consider your models, there are a few things to keep in mind. First, the pandemic as a tailing to growth in the first half of the expect the benefits to yearly reset over the remainder of the year. Also, we actively managed the impact of foreign exchange through our revenue saving program. To the extent we see further negative impact from foreign exchange, we will see additional benefits from our hedging in other revenues as we did in this quarter. Other revenue also includes supply to Organon and the Johnson & Johnson for its COVID-19 vaccine as well as we see related to our out licensing arrangements. In total, we expect other revenue to be higher in the second half versus first half of 2022. With respect to our products, for [indiscernible], we continue to expect a negative impact to U.S. sales, given the shift towards new adults pneumococcal vaccine. On Animal Health, we're seeing normalized industry growth rate as we adverse favorable trends in ending resulting from pandemic and experience foreign exchange headwinds. However, given our broad innovative portfolio, we are well positioned to continue to drive the market growth in 2022 and beyond. Finally, we continue to expect to look at full year sales of $5 billion to $5.5 billion, with second half sales weighted to the fourth quarter. Adaptation priorities remain unchanged. We will continue to clarify investments in our pipeline and business to realize the value of the many near and long-term opportunities in [indiscernible]. We continue to pursue compelling with strategic business development to augment our internal pipeline. Our recent collaboration with Orion is another example”